228 related articles for article (PubMed ID: 15479647)
21. Low-dose of thalidomide in the treatment of refractory myeloma.
Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
[No Abstract] [Full Text] [Related]
22. Thalidomide in refractory and relapsing multiple myeloma.
Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
[TBL] [Abstract][Full Text] [Related]
23. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
26. [Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
Aimono Y; Sato W; Otani E; Isa S; Sawahata T; Onozaki M; Saito Y; Ebata S; Aoyama Y; Hakozaki M; Suzuki M; Kudo D; Monma Y; Chikatsu N; Shinagawa A
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2579-84. PubMed ID: 22189222
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM
Clin Cancer Res; 2004 Sep; 10(17):5949-56. PubMed ID: 15355928
[TBL] [Abstract][Full Text] [Related]
28. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
29. Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
31. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
32. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wislöff F;
Br J Haematol; 2004 Apr; 125(2):149-55. PubMed ID: 15059136
[TBL] [Abstract][Full Text] [Related]
33. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
[TBL] [Abstract][Full Text] [Related]
34. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR
Acta Oncol; 2004; 43(2):215-6. PubMed ID: 15163174
[No Abstract] [Full Text] [Related]
35. [Thalidomide for the treatment of refractory multiple myeloma].
Kakimoto T; Hattori Y; Okamoto S
Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
[No Abstract] [Full Text] [Related]
36. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
[TBL] [Abstract][Full Text] [Related]
37. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
38. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
39. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
Hovenga S; Daenen SM; de Wolf JT; van Imhoff GW; Kluin-Nelemans HC; Sluiter WJ; Vellenga E
Ann Hematol; 2005 May; 84(5):311-6. PubMed ID: 15605244
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
